A crowded generics market makes gaining a strong foothold in the treatment of chronic pain challenging for branded agents. The treatment of chronic pain involves the use of drugs from several drug…
The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…
A crowded generics market makes gaining a strong foothold in the treatment of chronic pain challenging for branded agents. The treatment of chronic pain involves the use of drugs from several drug…
The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…
Fibromyalgia is a complex disease that is difficult to treat because of patient heterogeneity, frequent comorbid conditions, and numerous symptoms, including pain, depression, fatigue, and sleep…
The most highly anticipated analgesic drugs in late-phase development belong to the anti-nerve growth factor (NGF) class: Pfizer / Eli Lilly’s tanezumab and Regeneron / Teva / Mitsubishi Tanabe…
Abuse-deterrent formulations (ADFs) of opioid analgesics entered the U.S. pain market in 2010 as an attempt to slow the increasing rates of abuse/misuse and diversion stemming from chronic use of…
Fibromyalgia is a chronic condition characterized by pain and tenderness. The primary goal of treatment is to reduce the pain, for which multiple well-established treatment options are available,…
Interstitial cystitis/bladder pain syndrome (ICBPS) is a disorder characterized by chronic pain, discomfort, and pressure in the pelvic region that often includes symptoms of urinary frequency and…
Despite the extensive armamentarium of chronic pain therapies, which is increasingly subject to generic competition, the chronic pain market continues to represent a notable commercial…
As the prevalence of chronic pain associated with numerous indications (e.g., osteoarthritis, cancer) and of idiopathic origin (e.g., chronic back pain) continues to increase in the United States…
The prevalence of chronic pain associated with numerous indications (e.g., osteoarthritis, cancer) and of idiopathic origin (e.g., chronic back pain) continues to increase throughout the EU5. The…
Chronic pain is a broad term encompassing many nociceptive, inflammatory, and neuropathic pain subtypes that can result from complex mechanisms affecting multiple pathophysiological pathways in the…
Despite the extensive armamentarium of chronic pain therapies—and the fact that the market is increasingly subject to generics competition—the chronic pain market continues to represent a…
U.S. Physician and Payer Insights on New and Recently Launched Therapies and on the Impact of Expanding Generics The chronic pain market is sizeable in terms of both dollars and the potential…